Cisplatin (CDDP) and mitomycin C (MMC), two alkylating agents used against various solid tumours, are a common source of acute kidney injury. Thus, strategies for minimizing CDDP and MMC toxicity are of a clinical interest. In this study, we aimed to investigate the protective role of recombinant human erythropoietin (rhEPO) against oxidative stress and genotoxicity induced by CDDP and MMC in cultured Vero cells. Three types of treatments were performed: (i) cells were treated with rhEPO 24 h before exposure to CDDP/MMC (pre-treatment), (ii) cells were treated with rhEPO and CDDP/MMC simultaneously (co-treatment), (iii) cells were treated with rhEPO 24 h after exposure to CDDP/MMC (post-treatment). Our results showed that rhEPO decreased the reactive oxygen species levels, the malondialdehyde levels and ameliorated glutathione (reduced and oxidized glutathione) modulation induced by CDDP and MMC in cultured Vero cells. Furthermore, rhEPO administration prevented alkylating agents-induced DNA damage accessed by comet test. Altogether, our results suggested a protective role of rhEPO, against CDDP- and MMC-induced oxidative stress and genotoxicity, especially in pre-treatment condition.
RatcliffePJO’RourkeJFMaxwellPHPughCW. Oxygen sensing, hypoxiainducible factor-1 and the regulation of mammalian gene expression. J Exp Biol1998; 201: 1153–62.
5.
AnagnostouALeeESKessimianNLevinsonRSteinerM. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA1990; 87: 5978–82.
6.
AnagnostouALiuZSteinerMChinKLeeESKessimianNNoguchiCT. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA1994; 91: 3974–8.
7.
MorishitaEMasudaSNagaoMYasudaYSasakiR. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience1997; 76: 105–16.
8.
JelkmannW. Molecular biology of erythropoietin. Intern Med2004; 43: 649–59.
9.
SirenALFratelliMBrinesMGoemansCCasagrandeSLewczukP. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA2001; 98: 4044–9.
10.
GrassoGSfacteriaACeramiABrinesM. Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go?Neuroscientist2004; 10: 93–8.
11.
HanlonPRFuPWrightGLSteenbergenCArcasoyMOMurphyE. Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J2005; 19: 1323–5.
12.
SharplesEJPatelNBrownPStewartKMota-PhilipeHSheaffMKieswichJAllenDHarwoodSRafteryMThiemermannCYaqoobMM. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia reperfusion. J Am Soc Nephro2004; 15: 2115–24.
13.
ImamuraRMoriyamaTIsakaYNambaYIchimaruNTakaharaSOkuyamaA. Erythropoietin protects the kidneys against ischemia reperfusion injury by activating hypoxia inducible factor-1alpha. Transplantation2007; 83: 1371–9.
14.
SalahudeenAKHaiderNJenkinsJJoshiMPatelHHuangHYangMZheH. Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injury. Am J Physiol Renal Physiol2008; 294: 1354–1354.
15.
GobeGCEndreZHJohnsonDW. Administration of erythropoietin and its derivatives in renal disease: Advantages, mechanisms and concerns. Drug Discov Today Ther Strat2007; 4: 79–84.
Gnad-VogtSUHofheinzRDSausseleSKreilSWillerAWillekeFPilzLHehlmannRHochhausA. Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial. Anticancer Drugs2005; 16: 435–40.
20.
TayemYJohnsonTRMannBEGreenCJMotterliniR. Protection against cisplatininduced nephrotoxicity by a carbon monoxide-releasing molecule. Am J Physiol Renal Physiol2006; 290: 789–94.
21.
FuertesaMACastillabJAlonsoaCPerezJM. Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem2003; 10: 257–66.
22.
SiddikZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene2003; 22: 7265–79.
23.
LoiblSvon MinckwitzGSchwedlerKHöperDKaufmannMCostaSD. Mitomycin C, 5-fluoro uracil and folinic acid (Mi-Fu-Fo) as salvage chemotherapy in breast cancer patients with liver metastases and impaired hepatic function: a phase II study. Anti-Cancer Drugs2004; 15: 719–24.
24.
LiuKMittelmanASproulEEEliasEG. Renal toxicity in man treated with mitomycin C. Cancer1971; 28: 1314–20.
25.
ShiikiHDohiKNishiokaH. Glomerular tuft ballooning in mitomycin-C-induced renal impairment. Virchows Archiv A Pathol Anat1992; 420: 545–51.
26.
CvitkovicE. Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cancer Treat Rev1998; 24: 265–81.
27.
HaniganMHDevarajanP. Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther2003; 1: 47–61.
BaligaRUedaNWalkerPDShahSV. Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev1999; 31: 971–97.
30.
NathKANorbySM. Reactive oxygen species and acute renal failure. Am J Med2000; 109: 665–78.
31.
PremkumarKPachiappanAAbrahamSKSanthiySTGopinathPMRameshA. Effect of Spirulina fusiformis on cyclophosphamide and mitomycin-C induced genotoxicity and oxidative stress in mice. Fitoterapia2001; 72: 906–11.
32.
KlaunigEJWangZPuXZhouS. Oxidative stress and oxidative damage in chemical carcinogenesis. Toxicol Appl Pharmacol2011; 15: 86–99.
33.
NishikawaMNishiguchiSShiomiSTamoriAKohNTakedaTKuboSHirohashiKKinoshitaHSatoEInoueM. Somatic mutation of mitochondrial DNA in cancerous and noncancerous liver tissue in individuals with hepatocellular carcinoma. Cancer Res2001; 61: 1843–5.
34.
TsutsumishitaYOndaTOkadaKTakedaMEndouHFutakiSNiwaM. Involvement of H2O2 production in cisplatin-induced nephrotoxicity. Biochem Biophys Res Commun1998; 242: 310–2.
35.
YoshidaMFukudaAHaraMTeradaAKitanakaYOwadaS. Melatonin prevents the increase in hydroxyl radical spin trap adduct formation caused by the addition of cisplatin in vitro. Life Sci2003; 72: 1773–80.
36.
MazumdarMGiriSGiriA. Role of quercetin on mitomycin C induced genotoxicity: Analysis of micronucleus and chromosome aberrations in vivo. Mutat Res2011; 721: 147–52.
37.
SaadSYAl-RikabiAC. Protection effects of taurine supplementation against cisplatin-induced nephrotoxicity in rats. Chemotherapy2002; 48: 42–8.
38.
NazirogluMKaraogluAAksoyAO. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology2004; 195: 221–30.
39.
HuYJChenYZhangYQZhouMZSongXMZhangBZ. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol Trace Elem Res1997; 56: 331–41.
40.
TerasimaTYasukawaMBiological properties of Vero cells derived from the present stock. In: SimizuBTerasimaT (eds). Vero Cells: Origin, Properties and Biomedical Applications, Chiba, Japan: Department of Microbiology, School of Medicine, Chiba University, 1988.
41.
CathcartRSchwiersEAmesBN. Detection of picomole levels of hydrogenperoxide using a fluorescent dichlorofluorescein assay. Anal Biochem1983; 134: 111–6.
42.
GomesAFernandesELimaJL. Fluorescence probes used for detection of reactive oxygen species. J Biochem Biophys Methods2005; 65: 45–80.
43.
ChenTWongYS. Selenocystine induces caspase-independent apoptosis in MCF-7 human breast carcinoma cells with involvement of p53 phosphorylation and reactive oxygen species generation. Int J Biochem Cell Biol2009; 41: 666–76.
44.
Le BelCPIschiropoulosHBondySC. Evaluation of the probe 2’,7’- dichlorofluorescein as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol1992; 5: 227–31.
45.
OhkawaHOhishiNYagiK. Assay for lipid peroxide in animal tissues by thiobarbituric acid reaction. Anal Biochem1979; 95: 351–8.
46.
BradfordMM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein–dye binding. Anal Biochem1976; 72: 248–54.
47.
SinghNPMcCoyMTTiceRRSchneiderEL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res1988; 175: 184–91.
48.
CollinsARDusinskaMGedikCMStetinaR. Oxidative damage to DNA: do we have a reliable biomarker?Environ Health Perspect1996; 104: 465–9.
49.
LiGMaRHuangCTangQFuQLiuHHuBXiangJ. Protective effect of erythropoietin on beta-amyloid-induced PC12 cell death through antioxidant mechanisms. Neurosci Lett2008; 442: 143–7.
VotaDMMaltaneriREWenkerSDNesseABVittoriDC. Differential erythropoietin action upon cells induced to eryptosis by different agents. Biomed Pharmacother2010; 64: 681–5.
52.
DangJJiaRTuYXiaoSDingG. Erythropoietin prevents reactive oxygen species generation and renal tubular cell apoptosis at high glucose level. Cell Biochem Biophys2010; 64: 681–5..
53.
Rice-EvansCBurdonR. Free radical–lipid interactions and their pathological consequences. Prog Lipid Res1993; 32: 71–110.
54.
DraperHHSquiresEJMahmoodiHWuJAgarwalSHadleyM. A comparative evaluation of thiobarbituric acid methods for the determination of malondialdehyde in biological materials. Free Radic Biol Med1993; 15: 353–63.
DotanYLichtenbergDPinchukI. Lipid peroxidation cannot be used as a universal criterion of oxidative stress. Prog Lipid Res2004; 43: 200–27.
57.
SiddiqueYHAraGBegTJyotiGAfzalM. Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and curcumin in cultured human blood lymphocytes. Exp Toxicol Pathol2010; 62: 503–8.
58.
OztürkEDemirbilekSKöroğluAButABegeçZOGülecMAkyolOErsoyMO. Propofol and erythropoietin antioxidant properties in rat brain injured tissue. Prog Neuro-Psychopharmacol Biol Psychiatry2008; 32: 81–6.
59.
HalliwellB. Oxidative stress and cancer: have we moved forward?Biochem J2007; 401: 1–11.
60.
MeisterAAndersonME. Glutathione. Ann Rev Biochem1983; 52: 711–60.
61.
SunYZhouCPolkPNandaAZhangJH. Mechanisms of erythropoietin-induced brain protection in neonatal hypoxia-ischemia rat model. J Cereb Blood Flow Metab2004; 24: 259–70.
62.
KlaunigJEWangZPuXZhouS. Oxidative stress and oxidative damage in chemical carcinogenesis. Toxicol App Pharmacol2011; 254: 86–99.
63.
FreemanTAParviziJDella ValleCJSteinbeckMJ. Reactive oxygen and nitrogen species induce protein and DNA modifications driving arthrofibrosis following total knee arthroplasty. Fibrogenesis Tissue Repair2009; 2: 5–5.
